

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/495, 9/14	A1	(11) International Publication Number: WO 99/33467 (43) International Publication Date: 8 July 1999 (08.07.99)
(21) International Application Number: PCT/KR98/00436 (22) International Filing Date: 17 December 1998 (17.12.98) (30) Priority Data: 1997/81947 31 December 1997 (31.12.97) KR 1998/27730 10 July 1998 (10.07.98) KR (71) Applicant (for all designated States except US): CHOONG-WAE PHARMA CORPORATION [KR/KR]; 698, Shindae-bang-dong, Dongjak-gu, Seoul 156-757 (KR). (72) Inventors; and (75) Inventors/Applicants (for US only): JUNG, Jae, Young [KR/KR]; Choongwae Research Laboratory, 146-141, Annyung-ri, Taean-eup, Hwasung-gun, Kyunggi-do 445-970 (KR). KIM, Kye, Hyun [KR/KR]; Choongwae Research Laboratory, 146-141, Annyung-ri, Taean-eup, Hwasung-gun, Kyunggi-do 445-970 (KR). LEE, Sang, Heon [KR/KR]; Choongwae Research Laboratory, 146-141, Annyung-ri, Taean-eup, Hwasung-gun, Kyunggi-do 445-970 (KR). HONG, Ji, Woong [KR/KR]; Choongwae Research Laboratory, 146-141, Annyung-ri, Taean-eup, Hwasung-gun, Kyunggi-do 445-970 (KR). PARK, Jong, Woo [KR/KR]; Choongwae Research Laboratory, 146-141, Annyung-ri, Taean-eup, Hwasung-gun, Kyunggi-do		445-970 (KR). LEE, Kyu, Hyun [KR/KR]; Choongwae Research Laboratory, 146-141, Annyung-ri, Taean-eup, Hwasung-gun, Kyunggi-do 445-970 (KR). (74) Agent: KIM, Dong, Wan; 649-14, Yeoksam-dong, Kangnam-ku, Seoul 135-080 (KR). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: METHOD AND COMPOSITION OF AN ORAL PREPARATION OF ITRACONAZOLE (57) Abstract <p>The present invention relates to a method and composition of an oral preparation of itraconazole, an excellent azole antifungal drug. More particularly, it relates to an oral preparation of itraconazole having improved bioavailability, which is prepared by following steps of: i) dissolving itraconazole and hydrophilic polymer with solvent, ii) spray-drying said mixture, and iii) preparing the solid dispersions for oral preparation. The solid dispersions prepared in this invention may be useful in preparing tablets, granules and other oral dosage forms.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD AND COMPOSITION OF AN ORAL PREPARATION OF ITRACONAZOLE

TECHNICAL FIELD

The present invention relates to a method and composition of an oral preparation of itraconazole, an excellent azole antifungal drug. More particularly, it relates to a method and composition of an oral preparation of itraconazole having improved bioavailability, which is prepared by following steps of : i) dissolving itraconazole and hydrophilic polymer with solvent, ii) spray-drying said mixture, and iii) preparing the solid dispersions for oral preparation.

In other words, the present invention relates to an oral preparation of itraconazole, which has improved bioavailability by enhancing water solubility and rapidly being dissoluble regardless of food intake, prepared using a solid dispersions having itraconazole and pH-dependent, pharmaceutically safe, fastly dissolved at a low pH and hydrophilic polymer with the steps of i) dissolving and ii) spray-drying for the formation of an oral preparation of itraconazole having water-insoluble property.

BACKGROUND ART

Itraconazole or (\pm)-cis-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one, is a broadspectrum antifungal compound, and has been considered as an efficacious and safe drug.

Itraconazole has been developed as a broad antifungal agent for oral, parenteral and topical use and is disclosed in U.S.Pat.No. 4,267,179, but usually has been administered in oral route. Further, itraconazole is

efficacious in oral administration, because it has a tendency of extensive tissue distribution [*Mycoses* 32 (Suppl. 1), p67~87, 1989].

It has been reported that itraconazole has a pH-dependent solubility characterized in the ionization only at a low pH, such as, a gastric juice, and many attempts have been carried out to increase solubility and bioavailability, because itraconazole is almost insoluble in water (less than 1 μ g/ml) and in diluted acidic solution(less than 5 μ g/ml).

Generally, it has been reported that water insoluble drug has low dissolution property from the solid preparation. For increasing the solubility and dissolution rate of poorly water-soluble drugs, extensive studies of solubilization have shown that a wide variety of type of drugs can be efficiently solubilized by surfactants, hydrophilic carriers or pro-drugs, etc. Among them, a solid dispersion of drug and inert hydrophilic polymer has been suggested to enhance the solubility of insoluble drug. Further, many researches have been reported to enhance the solubility, dissolution rate and bioavailability of insoluble drug by preparing a solid dispersion of insoluble drug and inert carrier [①*International Journal of Pharmaceutics*, Vol. 104, p169~174(1994), ②*International Journal of Pharmaceutics*, Vol. 143, p247~253(1996)].

The term "a solid dispersion" defines a system in a solid state comprising at least two components, wherein one component is dispersed more or less evenly throughout the other component or components. Many factors have been known to affect the solubility of a solid dispersion.

Prior references related to oral preparation for increasing bioavailability of itraconazole are as follows :

- 1) The solubility and bioavailability of a drug are increased by complex using cyclodextrin or its derivative in WO 85/02767 and U.S.Pat.No. 4,764,604,
- 2) The aerosol preparation is prepared by reducing the particle size of a drug in WO 90/11754,
- 3) The liposomal preparation for external use including itraconazole is

prepared containing phospholipid and by solvent system in WO 93/15719,

4) The preparation for external use adhering to the nasal mucous membrane or the vaginal mucous membrane is prepared by emulsion or aqueous solution using cyclodextrin or its derivative in WO 95/31178,

5) The oral preparation to increase solubility and bioavailability of drug is disclosed in WO 94/05263, in which hydrophilic polymer such as hydroxypropyl methylcellulose is coated with about 25-30 mesh sugar spheres, and such preparation of itraconazole is commercially marketed as the trademark "SPORANOX",

6) The solid dispersions comprising drug and hydrophilic polymer according to the melt-extrusion method is disclosed in WO 97/44014, in which bioavailability is improved by increasing dissolution rate of drug and food effect is minimized according to the food intake.

Generally, there is a solvent method, a melting method or a solvent-melting method, etc. for preparing solid dispersions using hydrophilic polymer as carrier. In the solvent methods, a freezing drying method, a drying method or a nitrogen-gas drying method has not a few drawbacks, low reproducibility of preparation, the higher cost of preparation and long time in the preparation, etc. In the melting method, the careful attention of working process is demanded because raising temperature over melting point affects the stability of drug and cooling condition of melting mixture also affects the property of preparation. Further, even though a solvent-melting method is carried out when a solvent method or a melting method cannot be used alone, it has not a few drawbacks, for example, a lot of manipulation steps and time.

However, the spray-drying method used in this invention has some advantages, for example, short preparation time and maintaining low temperature, because the drug and the carrier dissolved in a solvent are immediately dried after spraying. Therefore, because the stability of drug is not affected by raising temperature, the spray-drying method is efficient in industrialization.

A disclosed preparation of WO 94/05263 is concerned with the beads

comprising a 25~30 mesh core, a coating film of a hydrophilic polymer and an antifungal agent, and a seal coating layer, and materials suitable for use in a fluidized bed granulator(GlattTM) with a Wurster bottom spray insert. A seal coating polymer layer is applied to the drug coated cores to prevent sticking of the beads which would have the undesirable effect of a concomitant decrease of the dissolution rate and of the bioavailability.

However, the reason why sugar sphere having appropriate dimensions(about 25-30 mesh) has to be used is to minimize the tendency toward agglomeration among sugar spheres in the drug coating process. In addition, during the preservation of the prepared beads filled in hard-gelatin capsules, sticking of the beads results in the undesirable decrease of the bioavailability. Therefore, a seal coating polymer layer has to be applied to the drug coated cores to prevent sticking of the beads. This is undesirable for demanding unnecessary step in the preparation.

On the other hand, the spraying rate in the preparation manufactured by said patent is regulated carefully to prevent undesirable drying or moisturization. Further, spraying air pressure is controlled to prevent formation of big bead and increasing of agglomeration during the coating process. Also, there is some drawbacks of spending the long time in drying, because fluidizing air volume has to be monitored carefully and inlet-air temperature has to be controlled.

The influence of food and dose on the oral bioavailability of itraconazole was studied. The relative systematic availability of itraconazole (PEG capsules) compared with solution averaged 40% in the fasting state but 102%(1.92 $\mu\text{g} \cdot \text{h}/\text{ml}$) in the post-prandial state. Food did not significantly affect the rate of absorption of the capsules. Areas under the curve at single doses of 50, 100 and 200mg had a ratio of 0.3 : 1 : 3, suggesting non-linear itraconazole pharmacokinetics in the range of therapeutically used doses. It was also concluded from the study that to ensure optimal oral absorption, itraconazole may be administered either in capsules shortly after a meal or in solution, the absorption of which is not influenced by the presence of food in the stomach [*Mycoses* 32 (Suppl. 1), p67~87, 1989].

Meanwhile, the solid dispersions using the melt-extrusion method in WO 97/44014 is prepared by following steps : i) mixing the itraconazole and pharmaceutically acceptable hydrophilic polymer, ii) optionally blending additives with the thus obtained mixture, iii) heating the thus obtained blend until one obtains a homogenous melt, iv) forcing the thus obtained melt through one or more nozzles, v) cooling the till it solidifies. Obtained solid dispersions is characterized in increasing dissolution rate of drug and lowering food effect, that is, bioavailability change of drug dependent upon the food intake.

The melting temperature and melting time of polymer and drug are important factors in the solid dispersions preparation by the melt-extrusion method disclosed prior reference. In this reference, it was reported that dissolution rate of solid dispersions is decreased at a low temperature, because drug and polymer are not melted sufficiently, and that polymer cannot be used at a higher temperature owing to decomposition of polymer.

Therefore, setting of melting temperature is very important. Further, to perform the cited method, extra equipment for preparing melt-extrusion and special technique to handle this equipment have to be required.

Particularly, hydrophilic polymers, such as, cellulose derivatives such as hydroxypropyl methylcellulose; natural gum such as tragacanth gum; polyvinylacetal diethylaminoacetate (trademark "AEA"); and polymethacrylic acid and its copolymer become char phase due to the decomposition of polymers on condition that melting time is long at relatively low temperature. The charred solid dispersions results in a serious problem of dissolution rate and stability of preparation due to the change of original character of polymer.

Also, the solid dispersions disclosed in prior reference is prepared by melt-extrusion and grinding to particles having the particle size less than 600 μm in the Fitzmill twice. Then, yield of preparation is relatively low as 78%. Further, there are some drawbacks of long preparation step by adding the grinding process.

The present invention has developed the oral preparation of itraconazole having improved bioavailability prepared by preparing the solid dispersions.

In this invention, the problems of prior method is solved by increasing pharmaceutical stability of heating, shortening of the manufacturing time and enhancing the yield of preparation using the spray-drying method in the solvent methods. Then, organic solvent is no longer remained in this method.

Also, the present invention developed the solid dispersions having itraconazole and pH-dependent, pharmaceutically safe, fastly dissolved at a low pH and hydrophilic polymer with the steps of i) dissolving and ii) spray-drying for the formation of an oral preparation of itraconazole having water-insoluble property. Further, the bioavailability of drug is improved and the food effect, that is, bioavailability change of drug dependent upon the food intake is minimized by increasing dissolution rate considerably in itraconazole preparation.

DISCLOSURE OF INVENTION

The object of the present invention is to provide an oral preparation of itraconazole having improved bioavailability, which is prepared by following steps of : i) dissolving 1 wt parts of itraconazole and 0.5~5.0 wt parts of pH-dependent inert hydrophilic polymer with at least one solvent selected from the group consisting of methylenechloride, chloroform, ethanol and methanol, ii) dispersing and spray-drying said mixture, and iii) preparing the solid dispersions for oral preparation.

Also, said pH-dependent inert hydrophilic polymer is at least one polymer selected from the group consisting of polyvinylacetal diethylaminoacetate and aminoalkyl methacrylate copolymer. And, said oral preparation of itraconazole is prepared by following compositions comprising 1.0~2.5 wt parts of said polymer as to 1 wt parts of itraconazole. Further, the concentration of solution dissolving itraconazole and pH-dependent inert

hydrophilic polymer is 3~10% (w/w), and inlet temperature is 30~60°C at spray-drying.

BEST MODE FOR CARRYING OUT THE INVENTION

Itraconazole has a weak basic property with pKa 3.7 and is ionized in acidic environment such as in the stomach. It has lipophilic property in nature, with oil / water partition coefficient being 5.66 in the pH 8.1 aqueous buffer / n-octanol system.

AEATM and EudragitTM E are hydrophilic polymers possessing the characteristic tertiary amine functional groups and are frequently used in protective or gastric soluble coating. Unlike other hydrophilic polymers, for example, Hydroxypropyl methylcellulose 2910, Methylcellulose, Hydroxyethylcellulose, Hydroxypropylcellulose, Sodium carboxymethylcellulose, etc. which release drug upon swelling, AEATM and EudragitTM E are solubilized under pH 5 in a pH-dependent manner, for increasing the dissolution profile of poorly water soluble drugs. The absorption of dissolved itraconazole from the stomach is not a problem in itself.

The pH-dependent hydrophilic polymer used in this invention, for example, polyvinylacetal diethylaminoacetate (trademark "AEA") or aminoalkyl methacrylate copolymer (trademark "Eudragit E") is dissolved in acid solution only at a pH in the range of 1~5. Further, 0.5~5.0 wt parts of said pH-dependent hydrophilic polymer, preferably, in the range of 1.0~2.5 wt parts of the polymer is contained as to 1 wt parts of insoluble drug. In case that the content of polymer is less than 0.5 wt parts, the solubility of drug with carrier shall decrease, because a solid dispersions is not formed completely, and such fact is confirmed by observing endothermic peak by melting of drug in Differential Scanning Calorimetry. In case that the content of polymer is more than 5.0 wt parts, initial dissolution rate shall decrease by polymer, and patient adaptability can be reduced by big size of preparation in taking drug.

The oral preparation in this invention is prepared by preparing the solid dispersions, which can be mass-produced in a large amount using spray dryer. The organic solvent, such as, methylenechloride or chloroform is used for dissolving insoluble drug and hydrophilic polymer before spray-drying, and methanol or ethanol can be mixed to said solution. The amount of solvent for spray-drying shall be required in the concentration of hydrophilic polymer to be 3~10% (w/w), preferably, 5% (w/w). Also, inlet temperature of dissolved mixture is 30~60°C, preferably, 35~45°C, and inlet amount of dissolved mixture can be changed properly according to the concentration of polymer. The yield of solid dispersions may be more than 95%.

Also, the solid dispersions used in this invention can be manufactured as not only tablet but form of oral preparation, such as, powder, granule, granule capsule, pellet capsule by the known method. Therefore, there are many choices in preparation development.

The diluent can be added to solid dispersions in order to manufacture oral preparation in this invention. For example, lactose, starch, sodium starch glycolate (ExplotabTM), crospovidone (Kollidone CLTM, Kollidone CL-MTM), croscarmellose sodium (AC-Di-SolTM) or maltodextrin (MaltrineTM) is used as a disintegrant in preparation. Further, stearic acid, magnesium stearate or talc is used as a lubricant.

The present invention will be more specifically explained by the following examples. However, it should be understood that the examples are intended to illustrate but not in any manner to limit the scope of the present invention.

EXAMPLES 1~7

Preparation of the solid dispersions by the spray-drying method

The solution for spray-drying is manufactured by following steps of :

i) dissolving polymer with methylenechloride as indicated Table 1., ii) adding 10g of drug to said polymer to be dissolved, and iii) filtering the mixture using 10 μ m filter. The concentration of hydrophilic polymer in solution is 5% (w/w). Buchi 190 mini spray dryer is used at spray-drying, inlet temperature is about 40°C and the rate of spray is 10ml/min.

Preparation of itraconazole tablet using solid dispersion by compaction granulation

A slug is prepared by constant pressing to the obtained solid dispersions, and the granule is prepared after grinding the slug. Obtained granule is sieved by passing the 35 mesh, and sieved granule is mixed with microcrystalline cellulose and pregelatinized starch (0.75 : 0.25) in the weight ratio of 1 : 1. KollidonTM CL is mixed as disintegrant, magnesium stearate is mixed as lubricant, and Cab-O-Sil and talc are mixed as glidant. Finally, tablets are obtained by compressing said mixture.

Also, the capsule is filled with mixture of said granule and suitable diluent, and the pellet can be manufactured by powder layering method using said solid dispersions by rotor tangential spray coater.

Table 1.

Composition of the oral preparation of itraconazole manufactured in examples 1~7

(unit : g)

Material	Example						
	1	2	3	4	5	6	7
Itraconazole	20	20	20	20	20	20	20
Eudragit TM E	10	20	30	40	10	5	0
AEA TM	10	5	5	0	20	30	40
Microcrystalline cellulose	30	33.75	41.25	45	30	41.25	45
Pregelatinized starch	10	11.25	13.75	15	10	13.75	15
Cab-O-Sil TM	1.2	1.35	1.65	1.8	1.2	1.65	1.8
Talc	1.2	1.35	1.65	1.8	1.2	1.65	1.8
Kollidon TM -CL	4	4.5	5.5	6	4	5.5	6
Mg. stearate	0.8	0.9	1.1	1.2	0.8	1.1	1.2

COMPARATIVE EXAMPLES 1~5

Preparation of the solid dispersions by the spray-drying method

The solution for spray-drying is manufactured by following steps of :
 i) dissolving polymer with methylenechloride as indicated Table. 2, ii) adding 10g of drug to said polymer and to be dissolved, and iii) filtering the mixture using 10 μ m filter. The concentration of hydrophilic polymer in solution is 5% (w/w). Buchi 190 mini spray dryer is used at spray-drying, inlet temperature is about 40°C and the rate of spray is 10ml/min.

Preparing the preparation by the spray-drying method

The granule suitable for tableting is manufactured by adding 10% of aqueous lactose solution to solid dispersions. The manufactured granule is converted into particle using 35 mesh sieve, and into particle using 35 mesh sieve after drying at 40°C for 1 day. The tablet is manufactured by following steps of : i) mixing dried granule with 35 mesh-passed lactose at

the ratio of 1:1 (w/w), ii) adding Explotab as disintegrant to said mixture, iii) adding magnesium stearate as lubricant to said mixture and to be lubricated, and iv) tableting the mixture.

Table 2.

Composition of the oral preparation of itraconazole manufactured in comparative example 1~5

(unit : g)

Material	Comparative example				
	1	2	3	4	5
Itraconazole	20	20	20	20	20
Eudragit TM L	30	-	-	-	-
Eudragit TM S	-	30	-	-	-
Eudragit TM RL	-	-	30	-	-
Eudragit TM RS	-	-	-	30	-
Hydroxypropyl methylcellulose 2910	-	-	-	-	30
Lactose	50	50	50	50	50
Explotab TM	5.0	5.0	5.0	5.0	5.0
Magnesium stearate	0.5	0.5	0.5	0.5	0.5

COMPARATIVE EXAMPLES 6~7

Preparation of the solid dispersions by the melting method

The solid dispersion is manufactured by following steps of : i) mixing polymer with drug at the ratio of 1:1.5 (w/w) using polymer as shown in Table 3., ii) agitating said mixture at 170°C, melting temperature of drug, to be melted, iii) cooling to room temperature, iv) grinding using hammer mill, and v) refining polymer using 35 mesh sieve.

Preparing the preparation by the melting method

The preparation is manufactured as the same manners of the example.

Table 3.

Composition of the oral preparation of itraconazole manufactured in comparative examples 6~7

(unit : g)

Material	Comparative example	
	6	7
Itraconazole	20	20
Eudragit TM E	30	-
Hydroxypropylcellulose 2910	-	30
Lactose	50	50
Explotab TM	5.0	5.0
Magnesium stearate	0.5	0.5

EXAMPLE 9**Comparative test of solubility of the solid dispersions in polymer**

This test is carried out by following steps of : i) laying itraconazole powder (equivalent to 25mg of itraconazole) and the solid dispersions (itraconazole:hydrophilic polymer = 1:1.5 (w/w)) to 20ml of test tube, ii) adding 10ml of simulated gastric juice (pH 1.2) for dissolution test in U.S.P. XXIII general experimental protocol to said mixture, iii) ultrasonic treating said mixture for 30 minutes to have sufficient moisty , iv) agitating it at 100 rpm for 24 hours in shaking water bath (25°C), v) centrifuging 5ml of each sample at 4,000 rpm for 20 minutes, vi) filtering supernatant using 0.45μm membrane, vii) centrifuging said supernatant at 14,000 rpm for 10 minutes again, and viii) collecting supernatant and analyzing content of drug by HPLC and determining solubility. The experimental result is shown in Table 4.

Table 4.

Comparative test of solubility of the solid dispersions in polymer

Test sample			Solubility ($\mu\text{g}/\text{ml}$)
solid dispersion	pH-independent hydrophilic polymer	Polyethylene glycol 20,000	16.54 ± 2.69
		Poloxamer 188	11.93 ± 1.03
		Povidone K 25	63.83 ± 4.27
		Hydroxypropyl methylcellulose	132.35 ± 8.14
	pH-dependent hydrophilic polymer	Eudragit [™] E	230.84 ± 2.58
		AEA [™]	264.83 ± 0.60
Itraconazole powder			1.38 ± 0.11
Number of test sample = 3, Average \pm Standard deviation			

The solid dispersions of itraconazole and pH-dependent hydrophilic polymer, such as, AEATM or EudragitTM E has excellent solubility as compared with the solid dispersions of itraconazole and pH-independent hydrophilic polymer, such as, polyethylene glycol, poloxamer, povidone or hydroxypropyl methylcellulose, and the result is shown in Table. 5. The solubility of said solid dispersions is improved about 170~200 times as compared with drug powder in simulated gastric juice (pH 1.2).

EXAMPLE 10

Comparative test of dissolution of the solid dispersions in polymer

The solid dispersionss (itraconazole : hydrophilic polymer = 1:1.5 (w/w)) manufactured using different polymers are tabletted. Then, dissolution test is carried out according to the dissolution test in U.S.P. XXIII general experimental protocol, and simulated gastric juice (pH 1.2 ± 0.1) is used as test solution. One tablet (equivalent to 100mg of itraconazole) is used and the amount of dissolved drug (% released) is measured in each time interval. The experimental result is shown in Table 5.

Table 5.

Comparative test of dissolution of the solid dispersions in polymer

Time Test sample			Amount of dissolved medicine (% Released)			
			5 min	10 min	30 min	60 min
solid dispersion	pH-independent hydrophilic polymer	Poloxamer 188	6.82±0.25	8.35±0.14	8.57±0.24	9.71±0.64
		Hydroxypropyl methylcellulose	7.16±0.78	19.55±1.44	48.90±1.30	64.87±1.25
		Povidone K 25	4.07±1.06	8.45±1.44	23.09±1.40	33.69±1.30
	pH-dependent hydrophilic polymer	AEA™	94.07±2.63	98.64±4.12	100.86±2.51	100.00±1.45
		Eudragit™ E	95.08±2.39	98.96±4.45	99.87±4.13	99.94±4.51
Number of test sample = 3, Average ± Standard deviation						

The solid dispersions of itraconazole and pH-dependent hydrophilic polymer, such as, AEA™ or Eudragit™ E has excellent dissolution rate, and the result is shown in Table 5.

EXAMPLE 11

Differential Scanning Calorimetry of itraconazole powder and solid dispersions

Differential Scanning Calorimetry (DSC) is carried out by following steps of : i) laying the solid dispersions (equivalent to about 5mg of itraconazole) of example 9 and itraconazole powder to aluminum melting pot, ii) purging nitrogen gas at 20ml/min, and iii) raising temperature at 10°C/min, and the solid dispersions is obtained.

NETZSCH DSC-200 (Germany) is used as differential scanning calorimeter. The solid dispersions of itraconazole and polymer, such as, polyethylene glycol(PEG) 20,000 or poloxamer 188 shows endothermic peak near 166°C by melting of itraconazole, but the solid dispersions of itraconazole and polymer, such as, povidone (Kollidone™ 25), hydroxypropyl

methycellulose (HPMC), EudragitTM E or AEATM doesn't.

Differential Scanning Calorimetry (DSC) is carried out after manufacturing solid dispersions, in which the weight-by-weight ratio of drug : pH-dependent hydrophilic polymer, such as, AEATM or EudragitTM E is from 1:0.5 to 1:2.

The endothermic peak of drug has a tendency to decrease according to increasing the content of pH-dependent hydrophilic polymer (AEATM, EudragitTM E), and solid dispersions having more than 1:1 of the weight-by-weight ratio of drug (itraconazole) : hydrophilic polymer (AEATM, EudragitTM E) doesn't show endothermic peak by melting of drug. Therefore, it is concluded that solid dispersions is formed at more than 1:1 of the weight-by-weight ratio of drug (itraconazole) : hydrophilic polymer (AEATM, EudragitTM E).

Differential Scanning Calorimetry (DSC) is carried out by using solid dispersions of itraconazole and piroxicam or benedipine hydrochloride. Single drug shows endothermic peak by melting of drug clearly, but solid dispersions doesn't. This results are disclosed in references [①*International Journal of Pharmaceutics*, Vol. 143, p59~66(1996), ②*Chemical Pharmaceutical Bulletin*, Vol. 44, No. 2, p364~371(1996)].

Also, to compare physical mixture of itraconazole and pH-dependent hydrophilic polymer (AEATM, EudragitTM E) with solid dispersions of this invention, Differential Scanning Calorimetry (DSC) is carried out. The physical mixtures having 1:1 and 1:2 of the weight-by-weight ratio of drug (itraconazole) : hydrophilic polymer (AEATM, EudragitTM E) show endothermic peak by melting of drug clearly.

EXAMPLE 12

Powder X-ray diffraction test of solid dispersions of itraconazole powder and polymer (AEATM, EudragitTM E)

Powder X-ray diffraction test is carried out in solid dispersions of itraconazole powder and polymer (AEATM, EudragitTM E). Enraf noinus FR 590 is used as instrument. The angle of diffraction according to the crystalline form of sample shows characteristic peak according to emitting X-ray at regular rate in Powder X-ray diffraction. Itraconazole shows characteristic peak of crystalline form, but solid dispersions doesn't. The crystalline form of itraconazole is transformed into amorphous form in solid dispersions. Therefore, it is concluded that solubility and initial dissolution rate is improved according to transformation of crystalline form into high energy amorphous form in preparation of solid dispersions, and this results are disclosed in reference (*International Journal of Pharmaceutics*, Vol. 123, p25 ~31(1995)).

Also, to compare physical mixture of itraconazole and pH-dependent hydrophilic polymer (AEATM, EudragitTM E) with solid dispersions of this invention, Powder X-ray diffraction test is carried out. The physical mixture having 1:1.5 of the weight-by-weight ratio of drug (itraconazole) : hydrophilic polymer (AEATM, EudragitTM E) shows characteristic peak of crystalline form.

EXAMPLE 13

Scanning electron microscopy test of solid dispersions of itraconazole powder and polymer (AEATM, EudragitTM E)

Scanning electron microscopy test is carried out in solid dispersions of itraconazole powder and polymer (AEATM, EudragitTM E). JEOL, JSM-35CF is used as instrument. The surface and particle size of sample is confirmed by observing at magnification of high power in Scanning electron microscopy.

Itraconazole powder shows several tens μm of particle distribution of crystalline form, but solid dispersions shows 1~5 μm of particle distribution of globular amorphous form. Therefore, it is concluded that solubility and initial dissolution rate is improved according to contacting with hydrophilic carrier closely due to small particle distribution in preparing solid dispersions, and this result is disclosed in reference (*International Journal of Pharmaceutics*, Vol. 123, p25~31(1995)).

EXAMPLE 14**Dissolution test**

The effect of a drug is measured *in vitro* according to the dissolution test in U.S.P. XXIII general experimental protocol. One tablet (equivalent to 100mg of itraconazole) is used as preparation for dissolution test. The tablet is manufactured by Paddle method, in which revolving speed of Paddle is 100rpm, temperature of dissolved solution is $37 \pm 0.5^\circ\text{C}$, and simulated gastric juice ($\text{pH } 1.2 \pm 0.1$) is used as test solution. 2ml of dissolved solution is collected at 5, 10, 30, 60 minutes, and 2ml of simulated gastric juice (37°C) is added to dissolved solution in each time. The amount of dissolved drug (% released) is measured by following steps of : i) centrifuging test sample, ii) filtering supernatant using $0.45\mu\text{m}$ membrane, and iii) analyzing content of drug by HPLC. Table 6. shows experimental result.

Table 6.

Time Example	Amount of dissolved medicine (% Released) (Number of test sample = 6, Average \pm Standard deviation)			
	5 min	10 min	30 min	60 min
Example 1	94.58 \pm 1.97	98.06 \pm 1.76	98.25 \pm 2.61	100.25 \pm 0.74
Example 2	95.07 \pm 2.44	98.28 \pm 0.78	99.86 \pm 1.68	99.51 \pm 1.01
Example 3	93.08 \pm 2.39	97.96 \pm 4.45	100.47 \pm 4.13	100.84 \pm 4.51
Example 4	96.87 \pm 3.53	98.93 \pm 1.61	99.80 \pm 2.74	100.32 \pm 2.32
Example 5	95.48 \pm 5.61	98.57 \pm 1.79	99.98 \pm 1.60	99.17 \pm 1.75
Example 6	94.91 \pm 5.98	98.61 \pm 2.93	100.47 \pm 1.29	100.81 \pm 2.16
Example 7	94.50 \pm 9.69	99.28 \pm 2.49	100.87 \pm 0.94	100.59 \pm 1.31
Comparative example 1	0	0	0.58 \pm 0.01	0.61 \pm 0.03
Comparative example 2	0	0	0.78 \pm 0.02	0.89 \pm 0.01
Comparative example 3	3.20 \pm 0.78	6.89 \pm 0.13	9.46 \pm 0.74	11.25 \pm 0.94
Comparative example 4	3.10 \pm 0.23	4.74 \pm 0.47	7.48 \pm 0.25	9.92 \pm 0.32
Comparative example 5	40.06 \pm 0.78	59.55 \pm 1.23	78.10 \pm 1.20	89.87 \pm 1.25
Comparative example 6	39.91 \pm 5.90	57.61 \pm 2.93	60.47 \pm 1.20	62.81 \pm 2.10
Comparative example 7	44.50 \pm 9.60	50.25 \pm 2.49	62.28 \pm 2.49	72.59 \pm 1.31
Comparative example	1.92 \pm 0.42	17.60 \pm 1.73	62.95 \pm 2.57	86.46 \pm 1.80
Comparative example: Capsule preparation (equivalent to 100mg of itraconazole) (trademark SPORANOX)				

The oral preparation manufactured by using solid dispersions (example 1~7) of this invention is dissolved very fastly and completely as compared with solid dispersions of comparative example in simulated gastric juice (pH 1.2), and the result is shown in Table 6.

EXAMPLE 15**Stability test**

Stability of preparation is confirmed by observing the change of dissolution rate of preparation according to laying samples at 40°C and 75% of relative humidity for 2 months. Table 7. shows experimental result.

Table 7.

Example	Amount of dissolved medicine (%) (time : 30 min)				
	initial	1 week	2 week	4 week	8 week
Example 1	95.28±2.61	94.25±1.68	95.34±1.74	93.47±2.10	94.35±1.34
Example 3	97.84±4.51	96.80±4.50	95.74±4.31	95.30±4.21	95.85±3.51
Example 6	99.81±2.16	98.80±2.10	97.86±2.11	96.51±2.10	94.61±2.14
Comparative example 6	62.81±1.20	62.75±2.11	59.71±2.30	55.51±2.11	50.51±1.90
Comparative example 7	62.27±1.31	57.50±1.29	55.51±1.30	51.54±1.29	46.69±1.24

REFERENCE EXAMPLE 1**Physical stability test of hydrophilic polymer in melting**

To confirm the thermostability of hydrophilic polymer in melting, phase change is observed apparently by laying polymers at the oven of 200°C for 5 minutes after adding hydrophilic polymer in glass mortar respectively. Physical stability of polymer in heating is determined by measuring ΔE before and after heating using Chroma Meter (CR-200, Minolta, Japan).

After laying hydrophilic polymers at the oven of 200°C for 5 minutes, the color of polymers is changed apparently, and a part of polymer is charred by being decomposed, and the result is shown in Table 8. The ΔE

value measured by Chroma Meter is 30~70. Therefore, it is suggested that polymer is decomposed or its property is changed by heating.

Table 8.

Experimental data of thermostability of polymer

Polymer	Color	ΔE
Methylcellulose	pale brown	50.52
Hydroxyethylcellulose	black, light charred	58.31
Hydroxypropylcellulose	light black	51.56
Hydroxypropyl methylcellulose 2910	black, light charred	60.45
Sodium carboxymethylcellulose	brown	56.48
Starch	pale yellow	34.53
Pectin	black, charred	44.83
Tragacanth	brown, light charred	55.77
Sodium alginate	black, light charred	57.34
Xanthan gum	black, charred	69.48
Carbopol 940	pale yellow	35.85
Polyvinylalcohol (M.W.78,000)	brown	49.15
Polyvinylpyrrolidone K-30	yellow	60.52
Polyethylene glycol 20,000	light black	53.35
Poloxamer 407	pale brown	47.28
AEA [™]	brown	52.56
Eudragit [™] E	pale brown	32.40
Eudragit [™] L	black	60.01
Eudragit [™] RL	brown	61.80
Eudragit [™] RS	pale brown	53.64
Eudragit [™] S	light black	56.62

WHAT IS CLAIMED IS :

1. An oral preparation of itraconazole having improved bioavailability, which is prepared by following steps of : i) dissolving 1 wt parts of itraconazole and 0.5~5.0 wt parts of pH-dependent inert hydrophilic polymer with at least one solvent selected from the group consisting of methylenechloride, chloroform, ethanol and methanol, ii) dispersing and spray-drying said mixture, and iii) preparing the solid dispersions for oral preparation.
2. The oral preparation of itraconazole according to claim 1, wherein the pH-dependent inert hydrophilic polymer is at least one polymer selected from the group consisting of polyvinylacetal diethylaminoacetate and aminoalkyl methacrylate copolymer.
3. The oral preparation of itraconazole according to claim 1, wherein 1.0~2.5 wt parts of said polymer is included as to 1 wt parts of itraconazole.
4. The oral preparation of itraconazole according to claim 1, wherein the concentration of solution dissolving itraconazole and pH-dependent inert hydrophilic polymer is 3~10% (w/w), and inlet temperature is 30~60°C at spray-drying.
5. The oral preparation of itraconazole according to claim 1, wherein the diluent is included to solid dispersions.
6. The oral preparation of itraconazole according to claim 1, wherein the solid dispersions is prepared as not only tablet but form of oral preparation, such as, powder, granule, granule capsule, pellet capsule.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 98/00436

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁶: A 61 K 31/495, 9/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁶: A 61 K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPIL, CAS (Questel)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94/05 263 A1 (JANSSEN PHARMACEUTICA N.V.) 17 March 1994 (17.03.94), claims 1-4,9,10; page 1, lines 21-34; page 3, lines 4-13; page 4, line 1- page 5, line 17.	1-6
Y	FR 2 722 984 A1 (LABORATOIRES EFFIK) 02 February 1996 (02.02.96), abstract; claims 1,3,4,5,6; page 4, lines 30-37; page 5, lines 17-19 in connection with page 6, line 5.	1-6
Y	WO 97/44 014 A1 (JANSSEN PHARMACEUTICA N.V.) 27 November 1997 (27.11.97), claims 1,5,6,11; page 5, line 35 - page 6, line 1.	1-6
Y	WO 96/39 835 A1 (EMISPHERE TECHNOLOGIES, INC.) 19 December 1996 (19.12.96), claims 1,2,10-13,15.	1-6
Y	EP 0 063 014 A2 (SANKYO COMPANY LIMITED), claims 1,3,4, 11,12; page 5, lines 11-17; examples 9b,10b; page 6, lines 1-10,19-20; page 8, lines 9-14,19-23.	1-6

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
08 February 1999 (08.02.99)

Date of mailing of the international search report
24 February 1999 (24.02.99)

Name and mailing address of the ISA/ AT
Austrian Patent Office
Kohlmarkt 8-10; A-1014 Vienna
Facsimile No. 1/53424/535

Authorized officer
Mazzucco
Telephone No. 1/53424/437

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 98/00436

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Database WPIL on Questel, week 8921, London: Derwent Publications Ltd., AN 89-156 775, Class A61K, JP 01 100 116 A (MITSUI TOATSU CHEM INC), abstract.	1,2,5,6
A	Database WPIL on Questel, week 8831, London: Derwent Publications Ltd., AN 88-214 423, Class A61K, EP 0 277 042 A (TAISHO PHARMACEUT KK), abstract.	1,2,5,6
A	EP 0 570 606 A1 (WAKAMOTO PHARMACEUTICAL CO., LTD), 24 November 1993 (24.11.93), claims 1,4,5,7-12; page 3, lines 8-29; page 4. lines 10-11. -----	1,2,5,6

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR 98/00436

Im Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche			Datum der Veröffentlichung Publication date Date de publication		Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets		Datum der Veröffentlichung Publication date Date de publication	
WO A1	9405263	17-03-94	AP	A0	9300563		31-10-93	
			AP	A	444		19-01-96	
			AT	E	145327		15-12-96	
			AU	B2	665867		18-01-96	
			CN	A	1088432		29-06-94	
			CN	B	1034714		30-04-97	
			CZ	A3	9500542		13-09-95	
			CZ	B6	283403		15-04-98	
			DE	C0	69306119		02-01-97	
			DE	T2	69306119		13-03-97	
			DK	T3	658103		09-12-96	
			EP	A1	658103		21-06-95	
			EP	B1	658103		20-11-96	
			ES	T3	2097536		01-04-97	
			FI	A	950975		02-03-95	
			FI	A0	950975		02-03-95	
			GR	T3	3022198		31-03-97	
			HR	A1	931158		30-06-95	
			HU	A0	9500642		28-04-95	
			HU	A2	70419		30-10-95	
			IL	A0	106871		28-12-93	
			IL	A1	106871		22-02-98	
			JP	T2	8501092		06-02-96	
			MX	A1	9305438		31-03-94	
			NO	A0	950829		02-03-95	
			NO	A	950829		02-03-95	
			NZ	A	255379		25-06-96	
			PL	A1	307791		26-06-95	
			PL	B1	172676		28-11-97	
			PL	B1	174178		30-06-98	
			SG	A1	48801		18-05-98	
			SI	A	9300461		31-03-94	
			US	A	5633015		27-05-97	
			ZA	A	9306493		02-03-95	
FR A1	2722984	02-02-96	AU	A1	30829795		26-02-97	
			EP	A1	761208		12-03-97	
			FI	A0	962978		26-07-96	
			FI	A	962978		20-01-97	
			FR	B1	2722984		18-10-96	
			JP	T2	10505574		02-06-98	
			US	A	5776495		07-07-98	
WO A1	9744014	27-11-97	WD	A1	9704749		13-02-97	
			AU	A1	29562797		09-12-97	
			CA	AA	2240161		27-11-97	
			CZ	A3	9801885		11-11-98	
			HR	A1	970270		30-04-98	
NO	A0	982599					05-06-98	
WO A1	9639835	19-12-96	AU	A1	61747796		30-12-96	
			EP	A1	831703		01-04-98	
			US	A	5750147		12-05-98	
EP A2	63014	20-10-82	DE	C0	3265352		19-09-85	
			EP	A3	63014		19-01-83	
			EP	B1	63014		14-08-85	
			ES	A1	511401		01-05-83	
			ES	A5	511401		31-05-83	
			ES	A1	8306019		01-08-83	
			JP	A2	57171428		22-10-82	
			JP	B4	63040131		09-08-88	
			US	A	4533562		06-08-85	
EP A1	570606	24-11-93	JP A2		4187630		06-07-92	